Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy ...
https://www.tipranks.com/news/the-fly/ventyx-biosciences-highlights-its-2025-pipeline-strategy Citius Pharma ( (CTXR) ) has released its Q4 earnings. Here is a ...
"I’m more just mad at myself for getting too caught up in the record and not caught up enough in the sprint finish," the ...
Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.
Las acciones de Citius Pharma cotizan y se negocian en la bolsa de valores NASDAQ. ¿Cuál es el símbolo bursátil de Citius Pharma? El símbolo bursátil de Citius Pharma es “CTXR”.
Hosted on MSN1mon
Citius Pharma Reports 2024 Financial Results and Business UpdateCitius Pharma ( (CTXR)) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pharmaceuticals, Inc. is a biopharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback